8 July 2024
Assura plc
Scrip Dividend Declaration
& Additional Listing
Assura plc ("Assura" or "the
Company"), the specialist healthcare property investor and
developer, today announces that 2,198,592 new Ordinary Shares ("the
New Shares") have been issued pursuant to the Scrip Dividend Scheme
(945,664) and relating to employee incentive schemes
(1,252,928).
Application has therefore been made
for the admission of the New Shares to the Official List of the
Financial Conduct Authority and to trading on the London Stock
Exchange's market for listed securities ("Admission"). The New
Shares will rank pari passu with the Company's existing ordinary
shares and Admission is expected to occur at 8.00am on 10 July
2024.
Following the allotment of the New
Shares, it is expected that the total number of shares in issue
will be 2,991,952,982 (none of which will be held in treasury) and
that, accordingly, the total number of voting rights of the Company
will be 2,991,652,982.
Scrip dividend scheme
Pursuant to its Scrip Dividend
Scheme and in response to the scrip dividend alternative for the
quarterly interim dividend payable on 10 July 2024 (the "Scrip
Dividend Alternative"), elections were received in respect of 1.7
per cent. of the Company's ordinary shares in issue as at the
record date of 7 June 2024.
Electing shareholders will receive
ordinary shares in the Company ("Shares") in lieu of cash in
respect of this dividend and, accordingly 945,664 Shares (the "New
Shares") will be issued by the Company to such
shareholders.
Copies of the documents relating to
the Scrip Dividend Alternative are available for inspection through
the National Storage Mechanism (https://data.fca.org.uk/#/nsm/nationalstoragemechanism).
This interim dividend is 100%
Property Income Distribution ("PID"). Forms
to register for gross PIDs (on future interim dividends) are
available on the Company's website. Please click here for
PID Forms.
Employee incentive schemes
A further 1,252,928 new Ordinary
Shares have been issued to the Assura plc Employee Benefit Trust in
order to satisfy the awards pursuant to the 2021 Performance Share
Plan, restricted share awards pursuant to the Performance Share
Plan and a free award to all eligible employees under the Share
Incentive Plan.
- ENDS
-
For more information, please
contact:
|
Assura plc
David Purcell, Investor Relations
Director
|
Tel: 0161 515 2043
Email: Investor@assura.co.uk
|
|
FGS
Global
Gordon Simpson
|
Tel: 0207 251 3801
Email: Assura@fgsglobal.com
|
Notes to Editors
Assura plc is the UK's leading
specialist healthcare property investor and developer. Assura
enables better health outcomes through its portfolio of more than
600 healthcare buildings, from which over six million patients are
served.
A UK REIT based in Altrincham,
Assura is a constituent of the FTSE 250 and the EPRA* indices. As
at 31 March 2024, Assura's portfolio was valued at £2.7 billion and
has a strong track record of growing financial returns and
dividends for shareholders.
At Assura, we BUILD for health,
having developed over 100 new healthcare buildings in our history,
and at the heart of our strategy sits The Bigger Picture; Healthy
Environment (E), Healthy Communities (S), Healthy Business
(G).
Further information is available
at www.assuraplc.com
Assura plc LEI
code: 21380026T19N2Y52XF72
*EPRA is a registered trademark of
the European Public Real Estate Association.